ZA200202757B - Compound with growth hormone releasing properties. - Google Patents

Compound with growth hormone releasing properties.

Info

Publication number: ZA200202757B
Authority: ZA; South Africa
Prior art keywords: growth hormone; compound; hormone releasing; releasing properties; trimethylhydrazinocarbonyl
Prior art date: 1999-11-10

Application number

ZA200202757A

Other languages

English (en)

Inventor

Michael Ankersen

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-10

Filing date

2002-04-09

Publication date

2003-02-26

2002-04-09 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

2003-02-26 Publication of ZA200202757B publication Critical patent/ZA200202757B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)

ZA200202757A 1999-11-10 2002-04-09 Compound with growth hormone releasing properties. ZA200202757B (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DKPA199901618		1999-11-10
US16710199P	1999-11-23	1999-11-23
PCT/DK2000/000624 WO2001034593A1 (en)	1999-11-10	2000-11-10	Compound with growth hormone releasing properties

Publications (1)

Publication Number	Publication Date
ZA200202757B true ZA200202757B (en)	2003-02-26

Family

ID=26065963

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200202757A ZA200202757B (en)	1999-11-10	2002-04-09	Compound with growth hormone releasing properties.

Country Status (23)

Country	Link
US (1)	US6576648B2 (xx)
EP (1)	EP1230236B1 (xx)
JP (2)	JP2003527338A (xx)
KR (1)	KR100907637B1 (xx)
CN (1)	CN1198818C (xx)
AT (1)	ATE280168T1 (xx)
AU (1)	AU782260B2 (xx)
BR (1)	BR0015407A (xx)
CA (1)	CA2387095C (xx)
CZ (1)	CZ301078B6 (xx)
DE (1)	DE60015173T2 (xx)
DK (1)	DK1230236T3 (xx)
ES (1)	ES2231279T3 (xx)
HU (1)	HU229445B1 (xx)
IL (1)	IL149049A0 (xx)
MX (1)	MXPA02004656A (xx)
NO (1)	NO323910B1 (xx)
PL (1)	PL199989B1 (xx)
PT (1)	PT1230236E (xx)
RU (1)	RU2272034C2 (xx)
UA (1)	UA73530C2 (xx)
WO (1)	WO2001034593A1 (xx)
ZA (1)	ZA200202757B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005097261A1 (en) *	2004-03-30	2005-10-20	Sapphire Therapeutics, Inc.	Method of reducing c-reactive protein using growth hormone secretagogues
US20130281701A1 (en)	2004-06-29	2013-10-24	Helsinn Therapeutics (U.S.), Inc.	Crystal forms of anamorelin
US7825138B2 (en) *	2004-06-29	2010-11-02	Helsinn Therapeutics (U.S.), Inc.	Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
AU2005272074B2 (en) *	2004-06-29	2011-11-24	Albany Molecular Research, Inc.	Crystal forms of (3r)-1-(2-methylalanyl-d-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
MX2007001477A (es) *	2004-08-12	2007-10-10	Sapphire Therapeutics Inc	Metodo para la estimulacion de la motilidad del sistema gastrointenstinal, que usa secretagogos de la hormona del crecimiento.
US8039456B2 (en)	2004-08-12	2011-10-18	Helsinn Therapeutics (U.S.), Inc.	Method of stimulating the motility of the gastrointestinal system using ipamorelin
JP2009542666A (ja) *	2006-06-30	2009-12-03	シェーリングコーポレイション	Ｐ５３活性を増加させる置換ピペリジンおよびその使用
MX2009008561A (es) *	2007-02-13	2010-01-15	Helsinn Therapeutics Us Inc	Metodo para tratar trastornos proliferativos celulares utilizando secretagogos.
TWI429436B (zh) *	2007-04-10	2014-03-11	Helsinn Therapeutics Us Inc	使用生長激素促泌素治療或預防嘔吐之方法
US8664267B2 (en) *	2007-04-12	2014-03-04	Academic Pharmaceuticals Incorporated	Parenteral solution containing amiodarone in NNDMA (N,N,-Dimethylacetamide)
JP5493870B2 (ja)	2008-02-08	2014-05-14	ゼリア新薬工業株式会社	３，８−ジアミノテトラヒドロキノリン誘導体
UA105657C2 (uk) *	2009-02-27	2014-06-10	Хелсінн Терапьютікс (Ю.Ес.), Інк.	Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar)	2012-04-20	2019-03-13	Ono Pharmaceutical Co	شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
CA2889499C (en)	2012-10-24	2019-09-10	Daiichi Sankyo Company, Limited	Growth hormone secretagogue receptor agonists for treating amyotrophic lateral sclerosis
CN107001323A (zh) *	2015-10-20	2017-08-01	江苏恒瑞医药股份有限公司	一种阿拉莫林的结晶形式及其制备方法
CN106187865A (zh) *	2016-07-08	2016-12-07	武汉工程大学	(r)‑1‑叔丁氧羰基‑3‑苄基‑3‑甲酸哌啶的合成及手性拆分方法
CN108129357B (zh) *	2016-12-01	2021-12-21	上海医药工业研究院	阿拉莫林中间体的制备方法
CN108239141A (zh) *	2016-12-23	2018-07-03	江苏先声药业有限公司	一种阿拉莫林的制备方法
CN115569120A (zh) *	2019-08-30	2023-01-06	赫尔森保健股份公司	具有改善稳定性的阿拉莫林片剂的生产方法
CN114805305B (zh) *	2022-04-20	2024-04-26	成都诺和晟泰生物科技有限公司	一种化合物及其应用
CN119792264B (zh) *	2025-03-14	2025-06-10	华中科技大学同济医学院附属同济医院	丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4839344A (en)	1987-06-12	1989-06-13	Eastman Kodak Company	Polypeptide compounds having growth hormone releasing activity
EP0400051B1 (en)	1988-01-28	1995-05-10	Polygen Holding Corporation	Polypeptide compounds having growth hormone releasing activity
AU633003B2 (en)	1988-05-11	1993-01-21	Polygen Holding Corporation	Polypeptide compounds having growth hormone releasing activity
IT1240643B (it)	1990-05-11	1993-12-17	Mediolanum Farmaceutici Spa	Peptidi biologicamente attivi contenenti in catena 2-alchiltriptofano
IL98910A0 (en)	1990-07-24	1992-07-15	Polygen Holding Corp	Polypeptide compounds having growth hormone releasing activity and pharmaceutical compositions containing them
US5663146A (en)	1991-08-22	1997-09-02	Administrators Of The Tulane Educational Fund	Polypeptide analogues having growth hormone releasing activity
US5492916A (en) *	1993-12-23	1996-02-20	Merck & Co., Inc.	Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
JPH10506091A (ja) *	1993-11-09	1998-06-16	メルクエンドカンパニーインコーポレーテッド	成長ホルモン放出促進性のピペリジン、ピロリジンおよびヘキサヒドロ−１ｈ−アゼピン類
AU684878B2 (en)	1993-11-24	1998-01-08	Merck & Co., Inc.	Compounds and the use thereof to promote the release of growth hormone(s)
US5721250A (en) *	1993-12-23	1998-02-24	Merck & Co. Inc.	Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
AU3434697A (en) *	1996-07-22	1998-02-10	Novo Nordisk A/S	Compounds with growth hormone releasing properties
PL341707A1 (en) *	1998-01-16	2001-04-23	Novo Nordisk As	Compounds exibiting growth hormone releasing properties
US6303620B1 (en) *	1998-05-11	2001-10-16	Novo Nordisk A/S	Compounds with growth hormone releasing properties
CN1142911C (zh) *	1998-05-11	2004-03-24	诺沃挪第克公司	具有释放生长激素特性的化合物
US20010020012A1 (en) *	2000-02-01	2001-09-06	Andersen Maibritt Bansholm	Use of compounds for the regulation of food intake

2000
- 2000-10-11 UA UA2002053785A patent/UA73530C2/uk unknown
- 2000-11-10 DE DE60015173T patent/DE60015173T2/de not_active Expired - Lifetime
- 2000-11-10 CN CNB008151458A patent/CN1198818C/zh not_active Expired - Lifetime
- 2000-11-10 PT PT00974349T patent/PT1230236E/pt unknown
- 2000-11-10 MX MXPA02004656A patent/MXPA02004656A/es active IP Right Grant
- 2000-11-10 HU HU0203844A patent/HU229445B1/hu unknown
- 2000-11-10 AU AU12694/01A patent/AU782260B2/en not_active Expired
- 2000-11-10 CZ CZ20021587A patent/CZ301078B6/cs not_active IP Right Cessation
- 2000-11-10 BR BR0015407-5A patent/BR0015407A/pt not_active Application Discontinuation
- 2000-11-10 KR KR1020027005836A patent/KR100907637B1/ko not_active Expired - Lifetime
- 2000-11-10 JP JP2001536540A patent/JP2003527338A/ja active Pending
- 2000-11-10 EP EP00974349A patent/EP1230236B1/en not_active Expired - Lifetime
- 2000-11-10 WO PCT/DK2000/000624 patent/WO2001034593A1/en not_active Ceased
- 2000-11-10 DK DK00974349T patent/DK1230236T3/da active
- 2000-11-10 RU RU2002115406/04A patent/RU2272034C2/ru active
- 2000-11-10 ES ES00974349T patent/ES2231279T3/es not_active Expired - Lifetime
- 2000-11-10 CA CA2387095A patent/CA2387095C/en not_active Expired - Lifetime
- 2000-11-10 PL PL356993A patent/PL199989B1/pl unknown
- 2000-11-10 AT AT00974349T patent/ATE280168T1/de active
- 2000-11-10 IL IL14904900A patent/IL149049A0/xx active IP Right Grant
2001
- 2001-03-26 US US09/817,840 patent/US6576648B2/en not_active Expired - Lifetime
2002
- 2002-04-09 ZA ZA200202757A patent/ZA200202757B/xx unknown
- 2002-05-08 NO NO20022200A patent/NO323910B1/no not_active IP Right Cessation
2008
- 2008-09-04 JP JP2008227447A patent/JP5053960B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1230236T3 (da)	2005-02-21
KR100907637B1 (ko)	2009-07-14
NO20022200L (no)	2002-05-08
CN1420878A (zh)	2003-05-28
CN1198818C (zh)	2005-04-27
DE60015173T2 (de)	2005-12-08
EP1230236B1 (en)	2004-10-20
NO323910B1 (no)	2007-07-16
ES2231279T3 (es)	2005-05-16
EP1230236A1 (en)	2002-08-14
HU229445B1 (en)	2013-12-30
CA2387095C (en)	2011-01-11
ATE280168T1 (de)	2004-11-15
RU2272034C2 (ru)	2006-03-20
UA73530C2 (uk)	2005-08-15
PL356993A1 (en)	2004-07-12
HUP0203844A2 (hu)	2003-03-28
DE60015173D1 (de)	2004-11-25
PL199989B1 (pl)	2008-11-28
JP2003527338A (ja)	2003-09-16
CZ20021587A3 (cs)	2002-09-11
HUP0203844A3 (en)	2004-07-28
MXPA02004656A (es)	2002-09-02
CA2387095A1 (en)	2001-05-17
AU1269401A (en)	2001-06-06
AU782260B2 (en)	2005-07-14
PT1230236E (pt)	2005-03-31
KR20020059694A (ko)	2002-07-13
US20010041720A1 (en)	2001-11-15
IL149049A0 (en)	2002-11-10
BR0015407A (pt)	2002-07-02
WO2001034593A1 (en)	2001-05-17
CZ301078B6 (cs)	2009-10-29
NO20022200D0 (no)	2002-05-08
US6576648B2 (en)	2003-06-10
JP5053960B2 (ja)	2012-10-24
JP2009062369A (ja)	2009-03-26

Publication	Publication Date	Title
IL149049A0 (en)	2002-11-10	Compound with growth hormone releasing properties
JO2371B1 (en)	2006-12-12	4-phenyl-pyridine derivatives
TW200642685A (en)	2006-12-16	Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
GEP20053600B (en)	2005-08-10	3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
BG106586A (en)	2003-01-31	Pyrazolopyramidines as therapeutic agents
IL176107A0 (en)	2006-10-05	Azabicyclic heterocycles as cannabinoid receptor modulators
WO2002042462A3 (en)	2003-06-19	Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
CA2534428A1 (en)	2005-03-03	Melanin concentrating hormone receptor antagonists
MXPA03008215A (es)	2004-01-29	Inhibidores de integrina alfa v beta 6.
CA2378613A1 (en)	2001-01-11	Selective iglur5 receptor antagonists for the treatment of migraine
DK1077941T3 (da)	2009-12-07	Forbindelser med væksthormonfrigörende egenskaber
EP1274443A4 (en)	2008-12-31	MICELLES
IL145684A0 (en)	2002-06-30	Treatment of pulmonary hypertension
AP2002002697A0 (en)	2002-12-31	Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
PL350568A1 (en)	2002-12-16	N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
NZ533358A (en)	2007-05-31	3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
DK1100824T3 (da)	2011-06-20	Forbindelser med væksthormonfrigivende egenskaber
BG106180A (en)	2002-08-30	Pharmaceutical composition containing sibutramine and orlistat
MY122477A (en)	2006-04-29	Sertraline oral concentrate
YU46302A (sh)	2005-06-10	Supstituisani piroli
PL341707A1 (en)	2001-04-23	Compounds exibiting growth hormone releasing properties
HUP0104820A3 (en)	2003-12-29	Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas
NO20012169L (no)	2001-05-02	Forbindelser med veksthormonfrigjörende egenskaper
BG106428A (en)	2003-04-30	Pharmaceutical compositions for treating psoriasis